Ryan Widau to Liver Neoplasms
This is a "connection" page, showing publications Ryan Widau has written about Liver Neoplasms.
Connection Strength
0.906
-
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 12 09; 27(12):e938-e948.
Score: 0.140
-
Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy. 2022 Nov; 14(16):1341-1351.
Score: 0.139
-
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305.
Score: 0.135
-
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver Int. 2021 11; 41(11):2759-2767.
Score: 0.128
-
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397.
Score: 0.124
-
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 03; 41(3):598-607.
Score: 0.122
-
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020.
Score: 0.117